Goldman Sachs
June 9, 2026
Teva Pharmaceuticals Annual Global Healthcare Conference Key Takeaways
Sector ReportEquitiesHealth Care
Teva Pharmaceuticals management outlined a focused 'pivot-to-growth' strategy at the 47th Annual Global Healthcare Conference, citing strong momentum in key branded products and pipeline advancement. The firm maintains a Buy rating, highlighting disciplined capital allocation and the stabilization of the generics business.
Key Takeaways
- 1.Management emphasized a 'pivot-to-growth' strategy, highlighting momentum in key branded products (Austedo, Ajovy, schizophrenia franchise) and an accelerating innovative pipeline.
- 2.Capital allocation remains a core focus, with discipline regarding investment-grade credit, potential share repurchases, and strategic funding partnerships for pipeline R&D.
- 3.The generics segment is stabilizing into a growth-generating franchise, driven by a strong biosimilars portfolio, notably Simlandi (bHumira) in the US.
Table of Contents
- Key Takeaways
- Disclosure Appendix
- GS Factor Profile
- M&A Rank
- Quantum
- Disclosures
- Company-specific regulatory disclosures
- Distribution of ratings/investment banking relationships
- Price target and rating history chart(s)
- Regulatory disclosures
- Global product; distributing entities
- General disclosures
- Ratings, coverage universe and related definitions
Document Preview
Access the Full Report
Get unlimited access to institutional research reports with a 14-day free trial.
Authors
Matt Dellatorre, Ph.D.Salveen RichterElizabeth Webster, Ph.D.Tommie ReerinkShrunatra MishraLydia ErdmanMark Aleynick
Securities
TEVA
Themes
Pivot-to-growth strategyCapital allocation disciplineBiosimilar momentum
Regions
GlobalEuropeUnited States